🇺🇸

Corporate Governance

· daily

US Corporate Board Director Changes SEC Filings — March 25, 2026

Across 36 SEC filings on USA Board Room Changes dated March 25, 2026, the dominant theme is executive and board turnover, with 18 resignations/retirements (e.g., Chairs, CFOs, directors) and 22 appointments/promotions, mostly neutral sentiment but positive in biotech (4/5) and finance (5/8). Period-over-period trends show mixed financial health: Generac FY2025 net sales $4.2B (implied strong YoY growth post-segments), Maze Therapeutics cash up 83% YoY to $360M (runway to 2028) despite net loss widening to $131.1M from $52.2M profit, no broad margin compression but R&D/G&A up 30-31% YoY in biotech. Insider activity absent, but capital allocation leans retention-focused (e.g., CEO extensions, RSU grants). Forward-looking catalysts cluster around 2026 AGMs (12+ retirements), Phase 2 trials (Maze mid/H2 2026), and spin-offs (Middleby Q2 2026). Portfolio-level pattern: internal promotions (7/22 appointments) signal continuity amid refreshes, bullish for stability in transforming sectors like midstream energy and cybersecurity; bearish risks from sudden CFO gaps (4 cases). Market implications: opportunities in experienced hires boosting governance in biotech/defense, watch for AGM successor announcements.

36 high priority 36 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 24, 2026

Across 42 DEF 14A proxy statements filed on March 24, 2026, a dominant theme is robust 2025 financial performance in energy, materials, and insurance sectors, with 12/42 filings highlighting YoY growth in key metrics like production (Magnolia +11%), net income (Nicolet +22%, Hamilton $576.7M), and cash flow (Albemarle OCF +86%, Eastman $1B). Capital allocation trends show strong shareholder returns, including $1.9B repurchases at Arch, 75% FCF returned at Magnolia ($322M total), and Vulcan's $700M dividends/buybacks, amid 16th consecutive dividend raise at Eastman. Mixed signals emerge in logistics (CH Robinson revenues -8.4% YoY but EPS +25.1%; Expeditors ocean decline), while governance focuses on say-on-pay votes (all recommending approval) and director elections cluster in May 2026. Notable M&A includes American Water's $3.7B capex and Essential Utilities acquisition by Q1 2027 end, plus Albemarle's $670M divestitures closing March 2026. Portfolio-level, 18/42 filings report positive YoY trends (avg revenue/sales growth ~10% where disclosed), signaling sector rotation into resources; risks center on delistings (BNB PLUS) and reorgs (Digimarc). Upcoming virtual annual meetings (35+ in April-May 2026) serve as catalysts for comp alignment and governance votes, with neutral sentiment in 60% but positive in high-materiality resource names.

42 high priority 42 total filings
· daily

US Executive Officer Management Changes SEC — March 24, 2026

Across 37 filings on USA executive and director changes dated March 24, 2026, a dominant theme is CFO turnover, with 10+ cases including a cluster of 6 New Mountain entities (e.g., Guardian IV BDC, Finance Corp) where Kris Corbett resigned as CFO effective post-transition by May 29, 2026, signaling potential short-term reporting risks but no disagreements noted. Positive internal promotions and experienced external hires dominate (e.g., Rush Enterprises COO, Dollar General CEO succession, Twilio/eBay board adds), reflecting proactive leadership refreshes amid sector growth, while high-materiality shocks like Simon Property Group CEO David Simon's death (10/10 materiality) and Indaptus Therapeutics' 96% change of control highlight acute vulnerabilities. Velo3D stands out with enriched financials: FY2025 revenue +12% YoY to $46M but gross margins cratered to -16.1% from -5.1% due to $7M write-downs, offset by $60-70M 2026 guidance and cash build to $39M (+3,150% YoY). Portfolio-level trends show neutral-to-positive sentiment in 70% of filings, with board expansions (e.g., Camp4, eBay) and retention incentives (e.g., Brag House RSUs replacing options) indicating management conviction; however, disputed CFO exits (FOXO) and planned retirements (Chesapeake, Solventum) cluster in finance/utilities. Implications: Investors should prioritize smooth successions for alpha (e.g., retail/tech) while monitoring BDC/fintech transition risks for volatility. No broad margin compression but isolated deteriorations (Velo3D -1,135 bps QoQ Q4); capital allocation leans toward equity incentives over buybacks/dividends.

37 high priority 37 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 24, 2026

Across 37 US SEC filings on boardroom changes dated March 24, 2026, a dominant theme is CFO and executive churn, particularly in private credit/BDC entities (New Mountain group: 13-15,17,18,20 with Kris Corbett resignations effective May 29, 2026), signaling potential leadership transitions amid sector pressures. Positive internal promotions and experienced external hires prevail in 70% of cases (e.g., RUSH, QuidelOrtho, eBay, Twilio, Dycom, American Airlines, Dollar General), boosting sentiment and stability in industrials, tech, and retail. Critical developments include Simon Property Group's CEO passing (materiality 10/10, mixed sentiment) with immediate family succession, Bitcoin Depot's CEO swap to fintech veteran Alex Holmes (9/10), and Indaptus Therapeutics' 96% control shift via $11.2M preferred stock sale (9/10 mixed). Portfolio-level trends show neutral/mixed sentiment in 45% of filings due to retirements/resignations without disputes, but no broad financial deterioration except Velo3D's FY2025 gross margins plunging to -16.1% from -5.1% YoY despite 12% revenue growth to $46M. Market implications favor monitoring fintech/retail for continuity premiums, while BDC/fund churn raises execution risks; overall, 18 positive appointments signal management deepening amid economic uncertainty.

37 high priority 37 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 23, 2026

Across 48 DEF 14A proxy statements filed March 23, 2026, companies emphasize strong 2025 performance with average reported revenue growth of 8-20% YoY in 12/48 filings (e.g., AbbVie +8.5% to $61.2B, Gallagher +20.7% to $13.7B), robust capital returns including dividend increases (AbbVie to $1.73/share, Kimberly-Clark 54th consecutive year), and buybacks (RLJ $28.6M), alongside governance enhancements like declassifying boards (AbbVie, Regions) and enabling special meetings (Molina, Regions). Key trends include outperformance vs. benchmarks (Progressive 1.6x S&P TSR, CME record volumes +6% YoY), margin resilience in services/insurance, but declines in consumer goods (Kimberly-Clark sales -2.1% YoY) and hospitality (RLJ constrained RevPAR). Critical developments feature leadership transitions (Intel new CEO Lip-Bu Tan, Entegris David Reeder), SPAC mergers (TETE to RADB), and pending deals (Kimberly-Clark $32B Kenvue H2 2026), signaling M&A momentum. Portfolio-level patterns show positive sentiment in 60% of filings (healthcare/financials leading), with high materiality (7-9/10) in 15 firms highlighting pay-for-performance alignment (e.g., Enpro 130.5% payouts). Market implications: Bullish for growth sectors, monitor May 2026 meetings for say-on-pay support gauging comp conviction.

48 high priority 48 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 23, 2026

Across 38 US SEC filings dated March 23, 2026, focused on boardroom changes, a dominant theme emerges of strategic leadership successions and transitions, with 12 positive sentiment cases (e.g., orderly CEO handovers in 4 Gladstone entities), 15 neutral director retirements/resignations, and 5 negative/mixed signals amid operational challenges like missed milestones. No broad YoY revenue growth trends reported, but period comparisons highlight BioAtla's 2025 bonus misses (0% payout) vs retention incentives for 2026 milestones, contrasting with reaffirmed FY26 outlooks (Cardinal Health). Insider-like conviction shines in internal promotions (e.g., Oil States CFO to CEO, Crawford interim to permanent) signaling stability, while 7 CEO/CFO departures raise continuity risks. Portfolio-level pattern: Biotech/healthcare (8 filings) shows 50% turnover rate with mixed milestones; finance/REITs (10 filings) emphasize governance separations (Chairman/CEO split). Forward catalysts cluster Q2 2026 (earnings, AGMs, milestones), implying near-term volatility but alpha in smooth transitions. Capital allocation leans retention bonuses/RSUs over buybacks, with no dividend/split changes noted.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 20, 2026

Across 50 DEF 14A proxy statements, a dominant theme is robust 2025 performance with 18 companies reporting YoY revenue growth averaging 10%+ (e.g., Ameriprise +6% rev/$18.2B, Goldman +9%/$58.3B, Inspire +14%/$912M, Eli Lilly $65.2B), strong EPS expansions (Goldman +27% to $51.32, Ameriprise +12% to $39.34), and margin improvements (Latham +320bps gross margins, Pentair +170bps adj ROS), though 6 showed declines like Avalon net income -76% YoY. Positive sentiment prevails in 22 filings (44%), mixed/neutral in 28, with no explicit insider selling but high ownership concentrations signaling alignment (e.g., Preformed Line 33% insiders). Capital allocation favors shareholders via dividend hikes (Ameriprise 21st consecutive +20% returns, Penske $182M buybacks/1.8% shares), buybacks, and LTIPs tied to CAGR targets. Portfolio-level trends highlight financials/healthcare outperformance vs industrials mixed results, with pay-for-performance evident (Cogent CEO 152% AWR target payout). AGMs cluster April 29-May 13, 2026 as key catalysts for comp votes, auditor ratifications, and equity plan amendments. Market implications: Buy dips in high-performers pre-vote, monitor pay scrutiny in decliners.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 20, 2026

Across 38 SEC filings on US executive and director changes dated March 20, 2026, the dominant theme is high C-suite and board turnover with 70% neutral sentiment, including 18 resignations/retirements (mostly voluntary, no disagreements cited except one), 12 appointments/promotions of experienced executives, and 5 salary/bonus adjustments signaling retention efforts. No widespread period-over-period financial deterioration evident, but isolated YoY EPS gains (e.g., Nu Skin) and equity grants contrast with severances totaling $810k+ across cases like Aeries ($265k), CleanCore ($500k), reAlpha ($46k). Biotech/pharma (Aquestive, AN2, Iovance) shows positive hires amid FDA catalysts, while tech (SMCI, Rigetti, Roblox) mixes promotions with legal risks and board exits. Portfolio-level pattern: 15 CFO/CIO changes suggest transition risks in growth sectors; insider conviction mixed with promotions (e.g., Kite Realty CFO) but concerns from disputes (APHP). Implications: Bullish for experienced hires in REITs/fintech, bearish for legal overhangs; watch Q2 2026 AGMs and successor searches for volatility.

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 20, 2026

Across 38 SEC 8-K filings on USA Board Room Changes from March 16-20, 2026, the dominant theme is high executive and director turnover, with 24 resignations/retirements (mostly neutral voluntary exits citing no disagreements) versus 14 appointments/promotions, signaling routine board refreshes amid stable operations but potential leadership gaps in tech, biotech, and financials. Positive hires bring deep sector expertise (e.g., ex-Coinbase CFO at Streamex, Dycom ex-CEO at Centuri), while negatives include a director resignation over financial planning disputes at American Picture House and a criminal indictment impacting Super Micro executives. No uniform period-over-period financial trends emerge as filings focus on governance, but isolated signals like Nu Skin's interim CFO crediting YoY EPS gains from cost cuts and BranchOut's retroactive salary hikes post-growth highlight pockets of operational strength. Materiality skews high (avg 6/10) for CEO/CFO shifts (12 cases), implying short-term execution risks but long-term strategic upgrades. Portfolio-level pattern: neutral sentiment in 70% of filings suggests low disruption risk, but watch clustered director retirements ahead of 2026 AGMs for governance evolution. Market implication: opportunities in experienced hire turnarounds, risks in unresolved successions.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 19, 2026

Across 50 DEF 14A filings, a dominant theme is robust 2025 performance highlighted in 17 positive/mixed sentiment proxies (e.g., revenue records at Vericel +20% CAGR, Occidental $10.5B OCF, TechnipFMC backlog +15% YoY), contrasting neutral governance-focused disclosures in 33 closed-end funds and REITs; period-over-period trends show YoY improvements in cash flows (e.g., TechnipFMC FCF +113%), dividends (Aflac +5.2%, BorgWarner +55%), and buybacks ($3.5B at Aflac), with rare declines like Aflac net earnings -29.2% YoY and Tronox 60% dividend cut. Capital allocation leans shareholder-friendly with $4.8B returned at Aflac and debt reductions (Occidental -$4B principal), signaling financial health amid economic challenges. Board refreshments are common (e.g., Sabre to 10 members, GEHC down to 8), with high say-on-pay support (Brunswick 97%, Tronox 96% avg last 7 yrs). A May 2026 cluster of 20+ annual meetings forms a catalyst calendar for say-on-pay votes and governance shifts. Portfolio-level, energy/industrials outperform (avg TSR +10-14%) vs flat funds, implying rotation into performers ahead of meetings.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 19, 2026

Across 27 filings on USA Executive & Director Changes from March 19, 2026, the dominant theme is neutral board and executive transitions (20/27 neutral sentiment), with routine director retirements/not standing for reelection (e.g., MediaAlpha, TripAdvisor, Tidewater) citing personal reasons and no disagreements, signaling stability rather than distress. Positive appointments dominate in financial services and healthcare (CVS Health, RGA, Array Technologies), adding audit/financial experts amid growth strategies, while isolated financial declines appear in hospitality (RCI Hospitality revenues -5.5% YoY to $279.4M, Bombshells -29.2% YoY). Period-over-period trends show outliers like Byrna Technologies' revenue surge >500% from $17M in 2020 to $118M in 2025 and RCI's share repurchases reducing shares 14% YoY to 7.71M, but no broad portfolio-level deterioration; net income improvements (RCI +$7.8M YoY) offset revenue softness. Forward-looking elements include 2026 compensation plans tying pay to EBITDA/revenue (MediaAlpha 25% PRSUs, Tigo 75% Adj EBITDA), bonus pools (Mercantile $1.21M target), and multiple 2026 annual meetings as catalysts. Capital allocation leans toward retention bonuses and RSUs over dividends/buybacks, with RCI's $45.4M FCF flat YoY highlighting reinvestment potential. Overall, low materiality (avg 5.6/10) suggests limited immediate volatility, but positive hires signal conviction in fintech/healthcare sectors.

27 high priority 27 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 19, 2026

Across 27 filings in the USA Board Room Changes stream (March 19, 2026), the dominant theme is neutral board and executive transitions, with 15/27 involving resignations or non-re-elections not due to disagreements, signaling routine refreshment rather than distress. Positive appointments dominate in financial services and energy sectors (e.g., CVS Health, RGA, Array Technologies), adding expertise in finance, reinsurance, and renewables amid strategic growth needs. Limited period-over-period data shows mixed financial health: RCI Hospitality revenues declined 5.5% YoY to $279.4M with Adjusted EBITDA down to $52.6M in 4Q25, contrasting Byrna Technologies' revenue surge from $17M (2020) to $118M (2025, +500%). No widespread insider selling or buying noted, but capital allocation highlights include RCI's 14% share reduction via buybacks and executive bonus plans tied to metrics like revenue/EBITDA in Tigo Energy and Mercantile Bank. Forward-looking catalysts cluster around 2026 annual meetings for director replacements and scheduled departures (e.g., Clear Secure GC April 3). Overall, low materiality (avg 5.6/10) suggests stable governance with opportunities in expertise-driven boards, but watch hospitality for ongoing SSS declines (-4.4% 4Q25).

27 high priority 27 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 18, 2026

Across 41 DEF 14A proxy statements, a dominant theme is strong 2025 financial performance in energy/utilities (e.g., Vistra's $5.912B Adjusted EBITDA exceeding guidance by $112M, NRG's 167% AIP EBITDA attainment) and financials (Wells Fargo's $21.3B net income, 12.4% ROE), with portfolio-level YoY revenue/earnings growth in 12/15 metric-disclosing firms averaging +15%, though mixed in semis/oil services (Lattice GAAP NI -95% YoY). Capital returns shine with $1.6B+ repurchases/dividends in multiple (NRG $1.65B, California Resources $513M), signaling management conviction amid robust governance (no hedging/pledging common). Merger activity (Black Hills-NorthWestern, California Resources-Berry) and CEO transitions (NRG, Regal Rexnord) add catalysts, with 30+ virtual annual meetings in late April-May 2026 as key voting events for comp approvals (97% prior support at Vistra). Sentiment skews positive/neutral (28/41), but outliers like premium declines (Assured Guaranty GWP down YoY) flag sector pressures. Implications: Bullish for utilities/energy on returns/growth; monitor REITs/banks for comp votes influencing retention.

41 high priority 41 total filings
· daily

US Executive Officer Management Changes SEC — March 18, 2026

Across 33 SEC filings on US executive and director changes from March 18, 2026, the dominant theme is high turnover with 18 appointments (CFOs, COOs, directors) and 15 departures/retirements, signaling proactive board refreshes in consumer (Coty) and energy sectors but potential instability in biotech (Hepion CEO resignation) and tech (SoundHound CFO exit). Sentiment skews neutral (20/33) with positive tones in 9 cases driven by experienced hires (e.g., Seadrill's Samir Ali, Waste Connections' Daniel Florness), while mixed in growth stories like Accelerant (24% YoY Q4 premium growth to $1.09B but $1.345B FY loss). Period-over-period data sparse but highlights Accelerant's outlier EBITDA surge 149% FY to $282M amid CFO change; no broad margin compression but continuity awards (Eagle $1.175M cash) flag CEO transitions. Portfolio-level patterns show CFO churn in 7 firms (40% small/mid-caps), board expansions in infra/healthcare, and comp-heavy inducements (LifeMD 675K RSUs). Implications: bullish for stable transitions with growth guidance (Accelerant Q1 EBITDA $64-66M), bearish for sudden exits amid suspensions (Graphjet); investors should monitor Q1 earnings for post-change execution.

33 high priority 33 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 18, 2026

Across 33 US SEC filings on board room changes from March 18, 2026, the dominant theme is high executive turnover, particularly CFOs and controllers (10+ cases including New ERA, McCormick, LifeMD, Accelerant, SoundHound, Cyber Enviro-Tech, MPLX), with 60% involving appointments of experienced internals/externals signaling stability amid growth pushes. Positive sentiment prevails in 30% of filings (e.g., Seadrill CEO promotion, Coty board refresh, LifeMD triple hires), neutral in 60% (resignations without discord), and mixed in key growth firms like Accelerant (24% YoY Q4 revenue to $1.09B but $1.345B FY loss) and SoundHound (8x revenue growth under departing CFO). Period trends show strong growth outliers like Accelerant EBITDA +149% FY to $282M and third-party premiums to 40% mix (from 21%), but misses like Playstudios FY2025 PSUs forfeited. Forward-looking includes Accelerant Q1 2026 EBITDA $64-66M and FY $275M+, with equity incentives tied to targets (e.g., VisionWave $100M revenue milestone). Capital allocation leans to retention via RSUs/PSUs (e.g., Eagle Bancorp $1.175M cash + RSUs, Playstudios new PSUs post-forfeit). Portfolio-level: Healthcare/biotech sees CEO volatility (Hepion sudden resign), energy stable promotions; actionable now: Buy dips on positive hires, watch transitions for volatility.

33 high priority 33 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 17, 2026

Across 38 DEF 14A filings filed March 17, 2026, a dominant theme is robust 2025 performance recaps with YoY growth in key metrics—e.g., Rollins double-digit revenue/earnings/cash flow (24th consecutive revenue growth year), CF Industries net earnings $1.46B (+implied strong YoY), Archrock NI +87% YoY/EBITDA +51% YoY/margins +600bps, Ball Corp record $13.16B sales/EVA/FCF/EPS—contrasting with mixed outlooks in cyclicals like Boise Cascade (flat 2026 construction) and Polaris (headwinds/divestiture). Capital allocation emphasizes shareholder returns totaling billions (CF $1.69B buybacks/dividends, Global Payments $1.5B, Archrock $212M), signaling management conviction amid neutral-to-positive sentiment (11 positive, 4 mixed). Governance highlights include board refreshes (e.g., T. Rowe Price +2 independents, Global Payments +3), independent majorities (e.g., Ball 8/9, AutoNation independent Chair), and standard proposals for elections/say-on-pay/auditors, with 20+ virtual meetings April-May 2026 as catalysts. No widespread insider selling detected; director ownership increases noted (Gran Tierra DSUs/PSUs YoY up). Portfolio-level: Industrials/energy outperform (6/10 positive), SPACs/cyclicals lag; pay-vs-performance XBRL disclosures (15+ filings) show alignment without major declines. Implications: Favor high-return firms pre-vote catalysts, monitor extensions/divestitures for downside.

38 high priority 38 total filings
· daily

US Executive Officer Management Changes SEC — March 17, 2026

Across 44 SEC filings on US executive and director changes from March 17, 2026, a net positive shift emerges with 22 appointments/promotions (51%) outpacing 20 resignations/retirements (45%), predominantly neutral but tilted positive in healthcare/biotech/tech sectors via high-caliber hires like ex-Air Force official at Redwire and Stryker CEO at GE HealthCare. Period-over-period trends in enriched data show robust revenue acceleration in biotechs (Bicycle Therapeutics +94% YoY Q4 collab rev to $48M, Neuronetics +86% YoY Q4 to $41.8M, +99% FY to $149.2M) but margin compression (Neuronetics gross margin -2370 bps YoY to 48.5%) and net losses widening (Bicycle FY -219M vs -169M). Critical developments include clustered resignations by Susan B. McGee from 6+ Goldman-related entities (filings 20-24,44), signaling potential portfolio consolidation, and Gran Tierra's 4-director exodus over audit disputes (filing 31). Capital allocation highlights include First Industrial's new $250M buyback (filing 3) and equity grants/RSUs across Coursera, Hinge Health, NWPX (filings 16,11,43). Forward-looking catalysts feature Neuronetics FY2026 rev guidance $160-166M, Cencora reaffirmed FY2026 adj EPS $17.45-17.75, and multiple AGMs Q2 2026. Portfolio implications: Favor firms with strategic hires amid transitions; monitor governance risks in energy/financials for volatility.

44 high priority 44 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 17, 2026

Across 44 SEC filings on USA Board Room Changes dated March 17, 2026, the dominant theme is extensive board and executive reshuffles, with 22 appointments/promotions (e.g., new directors/CEOs/CFOs) versus 20 resignations/retirements, 80% neutral sentiment but positive tilt from high-profile adds in healthcare/tech (e.g., Redwire, GE HealthCare, Neuronetics). Period-over-period trends in disclosed financials show robust revenue growth in biotechs (Bicycle Therapeutics +37.3% FY YoY to $72.6M, Neuronetics +99% FY to $149.2M) but margin compression (Neuronetics gross margin -2370 bps to 48.5%) and mixed net losses. No widespread insider selling detected, but capital allocation shines with First Industrial's new $250M buyback (no expiration) and DLH's equity plan expansion approved. Healthcare/biotech leads with 12 changes signaling stabilization amid R&D/cash runway extensions to 2030; energy flags risks from Gran Tierra's 4-director exodus over audit disputes. Portfolio implication: monitor succession risks in mature firms (e.g., Cencora CFO retire June 2026) versus growth refreshes offering alpha.

44 high priority 44 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 16, 2026

Across 43 DEF 14A filings dominated by 2026 proxy statements, overarching themes include robust 2025 financial performance in banks and energy firms (e.g., Trustmark NII +8.4% YoY to $647.2M, Marathon $4.0B net income), contrasted by cash flow deterioration (Unisys OCF -$140M from +$135.1M YoY) and SPAC distress (Trailblazer/Compass low trust balances risking dissolution). Capital returns are strong with $5.2B from Truist (+$10B buyback program), $4.5B from Marathon (dividend +10% YoY), and dividends across financials, signaling management conviction amid high say-on-pay support (Saia 96.9%). Governance enhancements like board refreshments (Truist additions, Trex retirements) and declassifications (Marathon) prevail, with reverse splits in 5 small caps/biotechs (NextPlat 1:50 max) indicating listing pressures. Period trends show revenue/earnings growth in 8/43 (avg +10-25% YoY where quantified), cost savings (Moderna 30% YoY), but expense rises (Trustmark +5.5%). A catalyst cluster of 30+ AGMs April 21-May 6, 2026, offers voting-driven volatility; favor outperformers like financials for relative strength vs. SPACs.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — March 16, 2026

Across 46 SEC 8-K filings dated March 16, 2026, focused on US executive and director changes, overarching themes include orderly retirements/successions (25+ cases, e.g., KORU Medical CEO to President Kalbermatten, Helmerich & Payne CFO transition), high-materiality C-suite shakeups (9 cases, avg materiality 8/10 like Baxter CFO exit, Fortune Brands turmoil), and positive board additions (12 cases with expertise in AI/tech/power, e.g., CoStar's Nana Banerjee, Flowserve's Brian Savoy). Period-over-period trends show mixed financials where disclosed: Dragonfly Energy +15.8% YoY FY2025 revenue ($58.6M) and +34.6% gross profit but widened net loss to $(69.9M); Kaltura Q4 revenue flat YoY ($45.5M) but Adjusted EBITDA +133% to $6.3M, FY +150% to $18.6M; CEA Industries Q3 net loss $(106.6M) from 28% BNB price drop. Capital allocation highlights shareholder alignment via equity grants (Victory Capital $79.4M performance shares with 100% appreciation hurdles over 7 years; Deere $35M PSUs tied to 5-year SVA); buybacks (Boston Beer $25M 10b5-1 plan). Market implications: Transition risks in healthcare/industrials (e.g., Air Industries CEO exit no successor), alpha in expert hires for growth (Planet Fitness 20.8M members + new CFO expert), sector patterns in energy/finance stability vs. crypto volatility.

46 high priority 46 total filings